Analysis Regeneron Pharmaceuticals Inc (REGN)
6/3/2024
Analysis of Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (REGN) has shown a consistent uptrend in the past few days. The stock price has been increasing steadily, with the RSI indicator showing values above 50, indicating bullish momentum. The MACD indicator has also been positive, with the MACD line consistently above the signal line.On May 31, the stock closed at $980.16, with the price reaching a high of $980.92. The RSI indicator was at 58.01, showing a healthy level of buying momentum. The MACD indicator was at 10.72, indicating a positive trend.
Overall, based on the technical indicators, Regeneron Pharmaceuticals Inc appears to be in a bullish phase, with the potential for further price appreciation in the near term. However, as with any investment, it is important to consider other factors such as market conditions and company news before making any trading decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary shows volatility with a beta of 1.264 and a fluctuation between the fifty-two-week low and high.
Valuation metrics indicate a high PEG ratio and price-to-book ratio, with the company being relatively expensive based on these metrics. The enterprise value, market capitalization, and price-to-sales ratio are also provided.
Lastly, dividends and splits information show the company's dividend dates, payout ratio, and dividend yields. The company has a history of dividends and stock splits, with a forward annual dividend rate and a trailing annual dividend rate.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown an increasing trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been growing consistently, with the company reporting a net income of $57.4 billion in 2020 and $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years, indicating improved profitability per share.
6. The company has been able to manage its operating expenses effectively, as seen in the stable or decreasing trend in expenses like research and development and selling, general, and administrative expenses.
7. Despite fluctuations in non-operating interests and other income/expenses, the company has maintained a strong financial performance with increasing EBIT and EBITDA figures.
8. The effective tax rate has also been relatively stable over the years, indicating consistent tax planning and management.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated but generally show an increasing trend.
3. Non-current assets have also been increasing steadily.
4. Total liabilities have been increasing, but at a slower pace compared to total assets.
5. Shareholders' equity has been increasing over the years.
6. The company has been investing more in non-current assets and retaining earnings to increase shareholders' equity.
7. The company has been managing its short-term and long-term debts effectively.
8. The company has been maintaining a healthy balance between assets, liabilities, and shareholders' equity.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance and payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability in operations and variability in financing and investing decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects an increase from the EPS of $5.67 from the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the quarterly and annual results over the specified periods.
Revenue estimate
The analysts' estimates for the future quarterly and annual sales of the company indicate a moderate growth trend.For the current quarter ending on June 30, 2024, the average estimate is $77,545,400,000, with a sales growth of 2% compared to the same period last year. The number of analysts providing estimates is 25.
Looking at the next quarter ending on September 30, 2024, the average estimate increases to $85,501,800,000, with a sales growth of 3% compared to the previous year. Again, 25 analysts have contributed to these estimates.
For the current fiscal year ending on September 30, 2024, the average estimate for total revenue is $357,772,000,000, showing a 1% growth from the previous year. The number of analysts providing estimates for the full year is 38.
In the following fiscal year ending on September 30, 2025, the average estimate for total revenue is projected to be $380,772,000,000, indicating a more significant growth of 6% compared to the previous fiscal year. The number of analysts remains at 38.
Overall, the estimates suggest a steady growth trajectory for the company's sales in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the past 5 years. However, the company is still projected to maintain a healthy growth rate over the next year and the next 5 years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average at $204.58. The current price of the security is $192.25, which is below the median and average forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
MACD of REGN
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
